secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001213900-25-108716
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reports Q3 net income of $108.6M, raises FY 2025 pro forma revenue guidance to $390-410M
--------------------------------------------------------------------------------

- Net revenue of $104.3M (pro forma $130.8M) driven by DefenCath sales of $88.8M; diluted EPS $1.26.
- FY 2025 pro forma net revenue guidance raised to $390-410M; Q4 guidance $115-135M; adjusted EBITDA guidance $220-240M.
- One-time $59.7M tax benefit from NOL carryforwards realization contributed to net income.
- Melinta acquisition closed Aug 29; integration ahead of schedule with ~$30M annual synergy run-rate expected by end 2025.
- Cash and short-term investments $55.7M at Sept 30; projecting year-end ~$100M; Phase III ReSPECT enrollment completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/0001213900-25-108716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/ea0265136-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-108716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer